Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies (NCT06028074)
A First-in-Human, Open-Label, Phase 1/2 Dose-Escalation With Enrichment and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of GIM-122 as a Single Agent in Adult Subjects With Advanced Solid Malignancies
🩺 Plain-English Summary (8th-Grade Level)
GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of intravenous (IV) administration of GIM-122 in adults with advanced malignancies.
Who can join: Review the eligibility criteria below.
Location: The Angeles Clinic and Research Institute — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (11 Sites)
- The Angeles Clinic and Research Institute — Los Angeles, California
- USC/Norris Comprehensive Cancer Center — Los Angeles, California
- UCLA Hematology/Oncology — Los Angeles, California
- UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California
- Florida Cancer Specialists — Sarasota, Florida
- Norton Cancer Institute — Louisville, Kentucky
- Rutgers Cancer Institute of NJ — New Brunswick, New Jersey
- Tennessee Oncology, PLLC — Nashville, Tennessee
- Texas Oncology - Baylor Sammons Cancer Center — Dallas, Texas
- NEXT Oncology Dallas — Irving, Texas
- Virginia Commonwealth University — Richmond, Virginia
📞 Contact the Study Coordinator
Phone: (210) 563-8441
Email: contact@lumabridge.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Malignancies
- Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER) — Houston, Texas
- Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies — La Jolla, California
- A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies — Baltimore, Maryland
- Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies — La Jolla, California
Explore by condition: All Advanced Solid Malignancies clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.